Inovio Pharmaceutical’s DNA Vaccine for Zika Virus Induces Robust Immune Responses in Preclinical Study

Inovio Pharmaceutical, 2/17/16

Biotech begins clinical manufacturing; expects to test Zika vaccine in humans in 2016

PLYMOUTH MEETING, Pa., Feb. 17, 2016 (GLOBE NEWSWIRE) — Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that preclinical testing of its synthetic vaccine for the Zika virus induced robust and durable immune responses, demonstrating the potential for a SynCon® vaccine to prevent and treat infections from this harmful pathogen. Health authorities have observed neurological and autoimmune complications potentially associated with Zika virus, including microcephaly in newborns and Guillain-Barre syndrome. Inovio is developing its Zika vaccine with GeneOne Life Sciences (KSE:011000) and academic collaborators.

Read more at Inovio Pharmaceutical. Read about the current clinical trial in Puerto Rico here.

Advertisements